Statistics

Total Visits

Views
Long-Term Survivors with EGFR Wild-Type Advanced NSCLC Treated with Second-Line Erlotinib: Subgroup Analysis from WILT Study36

Select a period of time:

Number of views in the range

Views
Long-Term Survivors with EGFR Wild-Type Advanced NSCLC Treated with Second-Line Erlotinib: Subgroup Analysis from WILT Study10

Views

Views
June 20251
July 20256
August 20251
September 20251
October 20250
November 20251
December 20250
Download CSV file
 untranslated
 untranslated

Top country views

Views
United States3
Mexico2
Argentina1
Brazil1
Ethiopia1
Hong Kong1
Turkey1
 

Top cities views

Views
Addis Ababa1
Antakya1
Coyoacán1
Dallas1
Henderson1
Hong Kong1
Recife1
San Carlos de Bolívar1
Schenectady1
Veracruz1